Rhinacanthus nasutus KURZ. (family Acanthaceae), has been used in Thai traditional medicine for the treatment of various diseases such as eczema, pulmonary tuberculosis, herpes, hepatitis, diabetes, hypertension and various skin diseases, and its active components were widely investigated.
The main bioactive compounds were revealed to be naphthoquinone; rhinacanthins (A-D, G-Q), rhinacanthone and lignan groups. [1] [2] [3] [4] [5] [6] [7] [8] 10, 11) Antitumor activity of R. nasutus KURZ. extracts, 8) and that of rhinacanthone in the in vivo study were reported. 11) We previously reported that rhinacanthins-M, -N and -Q and related naphthoquinone esters as well as synthetic compounds, 1,2-naphthoquinones and 1,4-naphthoquinones, selectively suppressed the growth of KB, HeLa and HepG2 human cancer cells, and normal Vero cells. 12, 13) We also performed mechanistic study and observed that synthetic rhinacanthins-N and -Q inhibited DNA topoisomerase II. 13) A naphthoquinone compound b-lapachone, that was also derived from natural products and has a similar structure to rhinacanthone, was reported to be a potent inhibitor of DNA topoisomerase I and II, [14] [15] [16] and to induce apoptosis of various cancer cells. [17] [18] [19] [20] [21] Recently, we observed that rhinacanthins-C, -N and -Q suppressed human cervical carcinoma HeLaS3 cells through induction of apoptosis. 22) Therefore, in the present study, we attempted to determine actual antitumor activity of rhinacanthins in tumor-bearing mice.
Since rhinacanthins-C, -N and -Q are hydrophobic compounds, they are not able to inject into bloodstream without solubilization. For in vivo use of the drugs, we attempted to solubilize them in liposomes. By the way, liposomes have been widely used in the field of drugs delivery systems (DDS): Liposomalization reduces side effects and toxicities of drugs encapsulated, and improves their bioavailability. Therefore, liposomes tended to be used for cancer treatment, since most of anticancer drugs accompany severe side effects. [23] [24] [25] Furthermore, liposomes with long circulating characteristics are known to accumulate in interstitial spaces of tumor tissues of which blood vessels are highly permeable. 26, 27) For the purpose of DDS, liposomes having rather rigid lipid bilayer are favorable, and they are usually composed of phospholipids with saturated fatty acyl chains and cholesterol. On the other hand, liposomes have been used for the injection of hydrophobic drugs, since hydrophobic materials can be encapsulated into the lipid bilayer of the liposomes. For example, Visudyne, a liposomal formulation of benzoporphyrin derivative monoacid ring A (BPD-MA), is being used clinically in photodynamic therapy for age-related macular degeneration. In Visudyne, liposomes are used as a "solvent" of BPD-MA for the purpose of injection of the drug into bloodstream. 28) In such case, liposomes having rather fluid lipid bilayer are used, and the injected drug in the bloodstream is transferred to lipoproteins, which, in turn, deliver the drug to the whole body. In this experiment, we used liposomes for the formulation of injectable rhinacanthins, which have limited solubility in water, and evaluated in vivo therapeutic efficacy in Meth-A sarcoma-bearing BALB/c mice.
MATERIALS AND METHODS

Materials
Egg yolk phosphatidylcholine (EPC) and egg yolk phosphatidylglycerol (EPG) were gifts of Nippon Fine Chemical Co., Ltd. (Takasago, Hyogo, Japan). Tetracolor ONE cell proliferation assay kit was purchased from the Seikagaku Co., Ltd., Tokyo, Japan. All other reagents and chemicals were of analytical grade. Rhinacanthins-C, -N and -Q (Fig. 1) were prepared as described previously. 22) In brief, dried roots of R. nasutus KURZ. (1.5 kg) were grounded and extracted with methanol. After removal of the solvent, C-NMR and MS).
13,22)
Preparation of Rhinacanthins-C, -N and -Q Entrapped Liposomes Rhinacanthin-entrapped liposomes were constructed of EPC and EPG with rhinacanthins-C, -N or -Q (6 : 3 : 1 as a molar ratio). Lipids and one of three rhinacanthins dissolved in chloroform were evaporated under reduced pressure after the addition of t-butyl alcohol. The residual mixture was then further lyophilized and hydrated with 0.3 M trehalose solution (Hayashibara, Biochemical Laboratory, Japan). The liposomal preparations were freeze-thawed for three cycles by using liquid nitrogen and sonicated for 15 min at 60°C. Finally, the liposomes were sized by extrusion thrice through a polycarbonate membrane filter with 100-nm pores (Nucleopore, Maidstone, U.K.). Particle sizes and z-potential of liposomes with entrapped three rhinacanthin drugs were recorded on an ELS 800 electrophoretic light-scattering spectrophotometer. For the determination of encapsulation efficiency of rhinacanthin drugs into the liposomes, an aliquot of the liposomal solutions was solubilized by the addition of 10% reduced Triton X-100 and the amount of drugs were optically determined at 257 nm for rhinacanthin-C and 253 nm for rhinacanthins-N and -Q, after the pH of the solutions had been adjusted to 1.0.
Spin Column Assay Spin column assay was performed as described previously with a slight modification. 28) Sepharose TM 4 Fast Flow (Amersham Pharmacia Biotech AB) was loaded into a 1-ml syringe with saline by centrifugation at 800 rpm for 30 s. Liposomes containing rhinacanthins-C or -N were mixed with an equal volume of HEPESbuffered saline (HBS, pH 7.4) or fetal bovine serum (FBS, Sigma Chemical Co., St. Louis, MO, U.S.A.), and incubated for 30 min at 37°C. Then, 100 ml of the liposomal solution was applied on the spin column and centrifuged at 500 rpm for 30 s, and the eluent was collected as the first fraction. Then, 100 ml of saline was applied to the column, and centrifugation was done at 500 rpm for 30 s to obtain the second fraction. The procedure was continued until the bedded volume fraction had been eluted. Each fraction obtained was mixed with 10% reduced Triton X-100 and the amount of rhinacanthins was determined with a photometer. Growth Assay of HeLaS3 Cells Human cervical carcinoma (HeLaS3) cells were maintained in Dulbecco's modified Eagle medium (DMEM), supplemented with 10% heatinactivated FBS, 1% kanamycin and 0.1% sodium bicarbonate. The cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 . For the growth assay, HeLaS3 cells were suspended in 200 ml of DMEM supplemented with 10% heat-inactivated FBS and seeded on a 96-well culture plate (5ϫ10 3 cells/well). After a 24-h incubation at 37°C, various concentrations of liposomal rhinacanthins-C, -N and -Q were added to each well to the final concentrations of 0, 3, 10, 30, 100, and 300 mM, and incubated for another 24, 48 or 72 h. At the end of each time point, the medium containing the drugs were discarded and the cells were washed with PBS (Ϫ). Subsequently, 10 ml of Tetracolor ONE solution and 190 ml of serum free DMEM medium were added to each well and then incubated at 37°C for 3 h. The amount of formazan formed was measured on a microplate reader at a test wavelength of 492 nm and a reference wavelength of 630 nm. Each assay was performed in quadruplicate. The IC 50 values were calculated from the mean of absorbance.
Therapeutic Experiment Meth-A murine sarcoma ascites cells (1ϫ10 6 cells/0.2 ml) were intraperitoneally (i.p.) inoculated and were grown in the abdomens of male BALB/c mice (SLC, Shizuoka, Japan). At 8 to 10 d later, the ascites was collected and centrifuged at 510 rpm in 4°C for 10 min. The supernatant was removed and washed 3 to 6 times with saline and kept the cells on ice before implantation. 26, 29) Mice were housed in cages with a 12-h light-12-h dark cycle. Food and water were available ad libitum. Animals were cared for according to the Guidelines for the Care and Used of Laboratory Animals of the University of Shizuoka.
Five week-old BALB/c male mice (body weight, 18.3Ϯ 0.9 g) were implanted subcutaneously (s.c.) into the left posterior flank with 1ϫ10 6 cells/0.2 ml of Meth-A sarcoma cells (day 0) and they were randomly divided into 4 groups (1 control and 3 treatment groups, each nϭ6). Liposomes containing rhinacanthins-C, -N or -Q at the dose of 5.0 mg/kg/d as rhinacanthins were administered i.p. into Meth-A sarcomabearing mice daily from day 1 to day 10. The control group was injected i.p. with 0.3 M trehalose solution. The size of the tumor and body weight of each mouse were monitored daily thereafter. Two bisecting diameters of each tumor were measured with slide calipers to determine the tumor volume and calculation was performed using the formula 0.4 (aϫb 2 ), where a is the largest diameter and b is the smallest one. The tumor volume thus calculated correlated well with the actual tumor weight (rϭ0.980). 26) The mean survival days from tumor implantation were determined for evaluating the lifeprolonging effects of rhinacanthins.
Statistical Analysis All data were expressed as the meanϮstandard deviation (S.D.). Differences between groups were described by the Student's unpaired t-test. p value less than 0.05 was considered statistically significant.
RRSULTS AND DISCUSSION
Liposomal Formulation of Rhinacanthins
Since rhinacanthins showed limited solubility in water, we had dissolved them in DMSO in the previous in vitro experiment. 22) Concerning the in vivo use, however, appropriate solvent is needed for dissolving the drugs instead of DMSO. By the way, Visudyne, clinically available liposomal BPD-MA, is formulated as liposomes because of limited solubility of BPD-MA in an aqueous media. Therefore, we attempted to prepare liposomal rhinacanthins for in vivo use of the drugs. Rhinacanthins-C, -N and -Q were liposomalized with EPC and EPG. These drugs were well dissolved in the liposomes: Encapsulation efficiencies were about 100% for all three rhinacanthins. The average sizes of rhinacanthins-C, -N and -Q liposomes were, 98.9 nm, 106.2 nm, and 100.3 nm, and the zpotentials for them were Ϫ36.4 mV, Ϫ45.4 mV, and Ϫ37.4 mV, respectively.
When liposomes are used as a solvent for hydrophobic materials, it is well known that the materials easily transfer from liposomal membrane to serum lipoproteins. Therefore, we determined the transfer of rhinacanthins-C and -N from liposomes to serum lipoproteins by use of spin column procedures. Figure 2 shows the typical elution pattern of rhinacanthin-N. Liposomes are known to be eluted at void volume (fractions 3, 4). As a result, rhinacanthins were eluted at the lipoprotein fractions (fractions 5-10 in the figure) when the liposomal rhinacanthins were incubated for 30 min in the presence of 50% FBS: The transfer % calculated from the elution profiles was 71.1Ϯ0.7% and 63.6Ϯ1.8% for rhinacanthins-C and -N, respectively. These data suggested that rhinacanthins injected into bloodstream would be delivered to various tissues including tumor tissue via the lipoproteins.
Antiproliferative Effects of Liposomal Rhinacanthins-C, -N and -Q on HeLaS3 Cells Next the antiproliferative effects of liposomal rhinacanthins-C, -N and -Q on HeLaS3 cells were measured by the Tetracolor ONE cell proliferation assay. As shown in Fig. 3 , the proliferation of HeLaS3 cells were significantly inhibited by rhinacanthins when the concentration of these drugs was increased (3-300 mM) as well as the exposure time was prolonged (24-72 h). These profiles of the antiproliferative effect was quite similar to that of DMSO-dissolved rhinacanthins as previously reported. 22) The IC 50 values of rhinacanthins-C, -N and -Q were 32, 17 and 70 mM for 24 h; 19, 17 and 52 mM for 48 h; and 2.7, 2.0 and 5.0 mM for 72 h, respectively. These data indicated that liposomal rhinacanthins showed a little bit stronger cytotoxicity compared with DMSO-dissolved ones. Furthermore, since the toxic effects of rhinacanthins appeared time-dependently and the strongest cytotoxicity was observed after 72 h incubation, the antiproliferative activities would be not due to direct toxicity against tumor cells but due to blocking of some proliferative steps. We previously observed that rhinacanthins-C, -N and -Q induced apoptosis of HeLaS3 cells through the activation of caspase 3. The cell cycle analysis by FACScan flow cytometry revealed that rhinacanthins induced accumulation of sub G1 hypodiploid cells in a dose dependent manner: apoptotic death was observed after 48 and 72 h whereas no significant change was observed after a 24-h incubation. Interestingly, rhinacanthin-treated cells were partly arrested at G2/M phase after 24 h exposure. 22) This result suggested the growth inhibitory effect of rhinacanthins might be due to cycle arrest during the G2/M phase that helps to prevent further damage and give the cell time to repair the defect, or undergoes apoptosis. 30) Liposomal rhinacanthins also damaged cells time-dependently, and strong cytotoxic action was observed after the 72-h incubation, suggesting that the mode of action of the liposomal rhinacan- Spin column assay was performed as described in the text. Liposomes containing rhinacanthin-N were mixed with an equal volume of HEPES-buffered saline (HBS, pH 7.4, A) or 50% FBS (B), and incubated for 30 min at 37°C. Then, 100 ml of the liposomal solution was applied on the spin column, and each 100 ml of saline was applied to the column for obtaining fractions. Each fraction obtained was mixed with 10% reduced Triton X-100 and the amounts of rhinacanthins were determined with a photometer.
Fig. 3. Antiproliferative Activities of Liposomal Rhinacanthins against HeLaS3 Cells
HeLaS3 cells (5ϫ10 3 cells/well) were seeded on a 96-well plate. After 24 h incubation, the cells were treated with liposomal rhinacanthins-C, -N and -Q at various concentrations of 0, 3, 10, 30, 100, and 300 mM, respectively (up to 100 mM is shown in the figure) . The cells were then incubated for 24 (A), 48 (B) and 72 h (C). Viability of the cells was determined by the absorbance at 492 nm after a 3-h incubation with Tetracolor ONE.
thins are similar to that of the DMSO-solubilized free drugs.
In Vivo Antitumor Activity of Liposomal Rhinacanthins In the previous therapeutic experiment in vivo, ethanolic and aqueous extracts of R. nasutus KURZ. from its roots and leaves were revealed to suppress Sarcoma 180 tumor growth in mice, and rhinacanthin-C was expected to be the bioactive compound. 8) Antitumor activity of rhinacanthone against Dalton's lymphoma-bearing mice was also reported. Fig. 5 ). The weight of each mouse, an indicator of side effects and tumor volume was monitored everyday after initiation of drug administration. Body weight loss of the tumor-bearing mice was observed only slightly when liposomal rhinacanthin-C was injected, whereas no substantial decrease was observed by the treatment with other compounds including the effective liposomal rhinacanthin-N (data not shown). These data indicate that the treatment by liposomal rhinacanthin drugs as injectable formulation markedly suppressed the tumor growth and enhanced the survival time of the Meth-A sarcoma-bearing BALB/c mice at a dose of 5.0 mg/kg/d.
Encapsulation of chemotherapeutic agents in liposomal formulations has shown decreased side effects and increased bioavailability of the drug to the target tissue, thereby leading to an enhanced therapeutic efficacy in patients. 31, 32) However, the purpose of liposomal formulation in this study was not for reducing side effects, but for making injectable form of hydrophobic drugs. 33) Furthermore, it is possible that rhinacanthins transferred to serum lipoprotein effectively accumulated in tumor tissues, since lipoproteins, especially low density lipoproteins, are known to deliver hydrophobic materials to tumor cells. [33] [34] [35] [36] In the present study, the results demonstrated for the first time that rhinacanthins-N, -Q and -C entrapped in liposomes showed antiproliferative activities against HeLaS3 cells: The activities were slightly higher than that of free drugs after 24-and 48-exposure. Corresponding to the in vitro data, these liposomal drugs effectively suppressed tumor growth and increased the survival of Meth-A sarcoma-bearing BALB/c mice. Among them, liposomal rhinacanthin-N was most potent compound ( pϽ0.05). We Previously observed that a C-3 hydroxy group on the naphthoquinone ring (R 5 ϭOH), two methyl substituents on the C-2Ј of propyl chain (R 1 and R 2 ), and naphthoate ester containing a hydroxyl group at C-1 and a methoxy group at C-4 on the naphthalene ring related with antiproliferative effects. 13) In the present study, we found that rhinacanthin-N was the most potent for tumor growth suppression in agreement with previous observation. Moreover, the naphthoate ester moiety in 1, 4 naphthoquinone structure might contribute antitumor activity in comparison with aliphatic ester. Finally, we conclude that liposomes are useful for injectable formulation of hydrophobic drugs. 
